Selective inhibition of ALDH1A3 is particularly important, as it may disrupt critical survival mechanisms in cancer cells, enhance tumour sensitivity to standard treatments, and limit the ability of CSCs to drive recurrence [24]. This evidence concerns the gene ALDH1A3 and neoplasm.